Following on from information provided to NICE by the company in June 2017, the appraisal of Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1037

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in June 2017, the appraisal of Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in June 2017, the appraisal of Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
01 February 2018 Suspended. This appraisal has been suspended. Empaglifozin is already recommended for people with type 2 diabetes (TA336) and the population for which this additional appraisal would be aimed at (poorly controlled diabetes plus cardiovascular risk) is already included in the population previously appraised. Cardiovascular endpoints are already part of the case for cost effectiveness of empagliflozin as established in TA336, therefore published NICE guidance already covers indication.
21 April 2017 Referral
21 April 2017 In progress. Topic referred
22 November 2016 - 20 December 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual